Table 3.
Comparison of the efficacy of NEPA and 5-HT3RA in patients receiving HEC and MEC.
| NEPA | 5-HT3RA | |||||
|---|---|---|---|---|---|---|
| HEC (n=32) |
MEC (n=74) |
P a | HEC (n=33) |
MEC (n=74) |
P a | |
| Chemotherapy duration | ||||||
| 2d | 11(34.4%) | 0(0.0%) | – | 21(63.6%) | 0(0.0%) | – |
| 4d | 21(65.6%) | 0(0.0%) | – | 12(36.4%) | 0(0.0%) | – |
| 5d | 0(0.0%) | 74(100.0%) | – | 0(0.0%) | 74(100.0%) | – |
| Complete Response | ||||||
| acute | 27(84.4%) | 56(75.7%) | 0.459 | 12(36.4%) | 34(45.9%) | 0.476 |
| delay | 24(75.0%) | 66(89.2%) | 0.115 | 10(30.3%) | 53(71.6%) | <0.001 |
| overall | 23(71.9%) | 53(71.6%) | 1.000 | 5(15.2%) | 30(40.5%) | 0.018 |
| Complete Control | ||||||
| acute | 20(62.5%) | 51(68.9%) | 0.674 | 6(18.2%) | 24(32.4%) | 0.200 |
| delay | 13(40.6%) | 55(74.3%) | 0.002 | 2(6.1%) | 34(45.9%) | <0.001 |
| overall | 10(31.3%) | 41(55.4%) | 0.038 | 1(3.0%) | 20(27.0%) | 0.009 |
| No emesis | ||||||
| acute | 29(90.6%) | 60(81.1%) | 0.347 | 13(39.4%) | 35(47.3%) | 0.583 |
| delay | 24(75.0%) | 69(93.2%) | 0.021 | 10(30.3%) | 54(73.0%) | <0.001 |
| overall | 24(75.0%) | 58(78.4%) | 0.898 | 6(18.2%) | 30(40.5%) | 0.041 |
| No significant nausea | ||||||
| acute | 23(71.9%) | 62(83.8%) | 0.252 | 12(36.4%) | 39(52.7%) | 0.176 |
| delay | 17(53.1%) | 60(81.1%) | 0.006 | 4(12.1%) | 46(62.2%) | <0.001 |
| overall | 15(46.9%) | 54(73.0%) | 0.018 | 3(9.1%) | 38(51.4%) | <0.001 |
aPearson’s Chi-squared test.